11,700
Views
76
CrossRef citations to date
0
Altmetric
Original Contributions

Multiple Naloxone Administrations Among Emergency Medical Service Providers is Increasing

, PhD, MA, , MD, MPH, , EMT, MPH, , MD, , MPH & , MD
Pages 411-419 | Received 28 Feb 2017, Accepted 30 Mar 2017, Published online: 08 May 2017

References

  • Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid overdose deaths-United States, 2000–2015. MMWR. 2016;65(50–51):1445–52.
  • Centers for Disease Control and Prevention (CDC). CDC grand rounds: prescription drug overdoses-a US epidemic. MMWR. 2012;Jan 13;61(1):10.
  • DuPont RL. Prescription drug abuse: an epidemic dilemma. J Psychoactive Drugs. 2010;Jun 1;42(2):127–32.
  • Lyapustina T, Rutkow L, Chang HY, et al. Effect of a “pill mill” law on opioid prescribing and utilization: the case of Texas. Drug Alcohol Depend. 2016;Feb 1;159:190–7.
  • Faul M, Bohm M, Alexander GC. Methadone prescribing and overdose and the association with medicaid preferred drug list policies — United States, 2007–2014. MMWR. 2017;66(12):320–3.
  • Chang HY, Lyapustina T, Rutkow L, et al. Impact of prescription drug monitoring programs and pill mill laws on high-risk opioid prescribers: a comparative interrupted time series analysis. Drug and alcohol dependence. 2016;Aug 1;165:1–8.
  • Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMSA. 2016;Apr 19;315(15):1624–45.
  • Alexander JL, Burton JH, Bradshaw JR, Colin F. Suspected opioid-related emergency medical services encounters in a rural state, 1997–2002. Prehosp Emerg Care. 2004;Jan 1;8(4):427–30.
  • Davis CS, Southwell JK, Niehaus VR, Walley AY, Dailey MW. Emergency medical services naloxone access: a national systematic legal review. Acad Emerg Med. 2014;Oct 1;21(10):1173–7.
  • Davis CS, Ruiz S, Glynn P, Picariello G, Walley AY. Expanded access to naloxone among firefighters, police officers, and emergency medical technicians in Massachusetts. Am J Public Health. 2014;Aug;104(8):e7–9.
  • Faul M, Dailey MW, Sugerman DE, Sasser SM, Levy B, Paulozzi LJ. Disparity in naloxone administration by emergency medical service providers and the burden of drug overdose in US rural communities. J Information. 2015;Jul;105(S3).
  • Fisher R, O'Donnell D, Ray B, Rusyniak D. Police officers can safely and effectively administer intranasal naloxone. Prehosp Emerg Care. 2016;Nov 1;20(6):675–80.
  • Barton ED, Colwell CB, Wolfe T, et al. Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting. J Emerg Med. 2005;Oct 31;29(3):265–71.
  • Kelly AM, Kerr D, Dietze P, Patrick I, Walker T, Koutsogiannis Z. Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose. Med J Aust. 2005;Jan 3;182(1):24–7.
  • Kerr D, Kelly AM, Dietze P, Jolley D, Barger B. Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. Addiction. 2009 Dec;1;104(12):2067–74.
  • Robertson TM, Hendey GW, Stroh G, Shalit M. Intranasal naloxone is a viable alternative to intravenous naloxone for prehospital narcotic overdose. Prehosp Emerg Care. 2009 Jan;1;13(4):512–5.
  • Merlin MA, Saybolt M, Kapitanyan R, et al. Intranasal naloxone delivery is an alternative to intravenous naloxone for opioid overdoses. Am J Emerg Med. 2010;Mar 31;28(3):296–303.
  • Dowling J, Isbister GK, Kirkpatrick CM, Naidoo D, Graudins A. Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther Drug Monitor. 2008 Aug;1;30(4):490–6.
  • Zuckerman M, Weisberg SN, Boyer EW. Pitfalls of intranasal naloxone. Prehosp Emerg Care. 2014;Oct 2;18(4):550–4.
  • Gladden RM. Fentanyl law enforcement submissions and increases in synthetic opioid–involved overdose deaths—27 states, 2013–2014. MMWR. 2016;65(33):837–43.
  • Rudd RA, Aleshire N, Zibbell JE, Matthew Gladden R. Increases in drug and opioid overdose deaths—United States, 2000–2014. MMWR. 2016;64:1378–82.
  • CDC. Increases in fentanyl drug confiscations and fentanyl-related overdose fatalities. HAN Health Advisory. Atlanta, GA: US Department of Health and Human Services, CDC, 2015. Accessed December 21, 2016. Available at: http://emergency.cdc.gov/han/han00384.asp.
  • Kitch BB, Portela RC. Effective use of naloxone by law enforcement in response to multiple opioid overdoses. Prehosp Emerg Care. 2016;Mar 3;20(2):226–9.
  • Food and Drug Administration. Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Meeting Announcement. October 5, 2016, Beltsville Maryland. Accessed December 21, 2016. Retrieved from: https://www.fda.gov/AdvisoryCommittees/Calendar/ucm516000.htm
  • Knowlton A, Weir BW, Hazzard F, et al. EMS runs for suspected opioid overdose: implications for surveillance and prevention. Prehosp Emerg Care. 2013lJul;1;17(3):317–29.
  • Lindstrom HA, Clemency BM, Snyder R, Consiglio JD, May PR, Moscati RM. Prehospital naloxone administration as a public health surveillance tool: a retrospective validation study. Prehosp Disaster Med. 2015;Aug;1;30(04):385–9.
  • Merchant RC, Schwartzapfel BL, Wolf FA, Li W, Carlson L, Rich JD. Demographic, geographic, and temporal patterns of ambulance runs for suspected opiate overdose in Rhode Island, 1997–2002. Subst Use Misuse. 2006;Jan 1;41(9):1209–26.
  • Mann NC, Kane L, Dai M, Jacobson K. Description of the 2012 NEMSIS public-release research dataset. Prehosp Emerg Care. 2015;Apr 3;19(2):232–40.
  • Wheeler E, Jones TS, Gilbert MK, Davidson PJ. Opioid overdose prevention programs providing naloxone to laypersons—United States, 2014. MMWR. 2015;Jun 19;64(23):631–5.
  • Clarke SF, Dargan PI, Jones AL. Naloxone in opioid poisoning: walking the tightrope. Emerg Med J. 2005;Sep 1;22(9):612–6.
  • Wampler DA, Molina DK, McManus J, Laws P, Manifold CA. No deaths associated with patient refusal of transport after naloxone-reversed opioid overdose. Prehosp Emerg Care. 2011;Jun 8;15(3):320–4.
  • Levine M, Sanko S, Eckstein M. Assessing the risk of prehospital administration of naloxone with subsequent refusal of care. Prehosp Emerg Care. 2016;Mar;16:1–4.
  • Willman MW, Liss DB, Schwarz ES, Mullins ME. Do heroin overdose patients require observation after receiving naloxone? Clin Toxicol. 2016;Nov;16:1–7.
  • Carr BG, Caplan JM, Pryor JP, Branas CC. A meta-analysis of prehospital care times for trauma. Prehosp Emerg Care. 2006 Jan;1;10(2):198–206.
  • Weiner SG, Mitchell PM, Temin ES, Langlois BK, Dyer KS. Use of intranasal naloxone by basic life support providers. Prehosp Emerg Care. 2017;Feb;6:1–5. doi: 10.1080/10903127.2017.1282562. (Epub ahead of print).
  • Sumner SA, Mercado-Crespo MC, Spelke MB, et al. Use of naloxone by emergency medical services during opioid drug overdose resuscitation efforts. Prehosp Emerg Care. 2016;Mar 3;20(2):220–5.
  • Boyer EW. Management of opioid analgesic overdose. NE J Med. 2012;Jul 12;367(2):146–55.
  • Burillo-Putze G, Miro O. Tintinalli's Emergency medicine: a comprehensive study guide. 8th ed. Opioids, 2015; Chapter 186. McGraw Hill Education.
  • Garza A, Dyer S. EMS data can help stop the opioid epidemic. J Emerg Med Serv. 2016;Nov. 1;
  • Drug Enforcement Agency. DEA issues Carfentanil warning to police and public dangerous opioid 10,000 times more potent than morphine and 100 times more potent than fentanyl. DEA Public Affairs Office, September 22, 2016. Available at: https://www.dea.gov/divisions/hq/2016/hq092216.shtml. Accessed March 29, 2017.